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Abstract 
Background:	Outpatient	anticoagulation	clinics	were	initially	developed	to	care	for	
patients	taking	vitamin	K	antagonists	such	as	warfarin.	There	has	not	been	a	system-
atic	evaluation	of	the	barriers	and	facilitators	to	integrating	direct	oral	anticoagulant	
(DOAC)	care	into	outpatient	anticoagulation	clinics.
Methods:	We	performed	a	mixed	methods	study	consisting	of	an	online	survey	of	
anticoagulation	clinic	providers	and	semi-	structured	interviews	with	anticoagulation	
clinic	leaders	and	managers	between	March	and	May	of	2017.	Interviews	were	tran-
scribed	and	coded,	exploring	for	 themes	around	barriers	and	facilitators	 to	DOAC	
care	 within	 anticoagulation	 clinics.	 Survey	 questions	 pertaining	 to	 the	 specific	
themes	identified	in	the	interviews	were	analyzed	using	summary	statistics.
Results:	Survey	responses	were	collected	from	159	unique	anticoagulation	clinics	and	
20	semi-	structured	interviews	were	conducted.	Three	primary	barriers	to	DOAC	care	
in	the	anticoagulation	clinic	were	described	by	the	interviewees:	(a)	a	lack	of	provider	
awareness	for	ongoing	monitoring	and	services	provided	by	the	anticoagulation	clinic;	
(b)	financial	challenges	to	providing	care	to	DOAC	patients	in	an	anticoagulation	clinic	
model;	 and	 (c)	 clinical	 knowledge	 versus	 scope	of	 care	 by	 the	 anticoagulation	 staff.	
These	themes	linked	to	three	key	areas	of	variation,	including:	(a)	the	size	and	hospital	
affiliation	of	 the	anticoagulation	clinic;	 (b)	 the	use	of	 face-	to-	face	versus	 telephone-	
based	care;	and	(c)	the	use	of	nurses	or	pharmacists	in	the	anticoagulation	clinic.
Conclusions:	Anticoagulation	clinics	in	the	United	States	experience	important	barri-
ers	to	integrating	DOAC	care.	These	barriers	vary	based	on	the	clinic	size,	model	for	
warfarin	care,	and	staff	credentials	(nursing	or	pharmacy).
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1  | INTRODUCTION
Outpatient	anticoagulation	clinics	were	 initially	developed	to	opti-
mize	care	 for	patients	 taking	vitamin	K	antagonists,	primarily	war-
farin.1	 Expert	 nurses	 and	pharmacists	within	 these	 clinics	 provide	
high-	level	 care	 leading	 to	 improved	 patient	 satisfaction	 and	 high-	
quality	warfarin	management.	In	recent	years,	the	use	of	direct	oral	
anticoagulants	 (DOACs)	 for	 patients	who	 traditionally	would	 have	
received	warfarin	therapy	has	grown	rapidly.2	While	these	DOAC-	
treated	 patients	 face	 many	 of	 the	 same	 challenges	 as	 warfarin-	
treated	 patients,	 they	 do	 not	 require	 frequent	 dose	 changes	 or	
blood	work.	Despite	calls	for	an	evolution	in	anticoagulation	clinics	
services,	 including	care	of	DOAC-	treated	patients,	 anticoagulation	
clinics	have	largely	been	underutilized	for	these	DOAC	patients.3
To	 better	 understand	 how	 anticoagulation	 clinics	 have	 responded	
to	the	growth	 in	DOAC	use,	we	conducted	a	mixed-	methods	study	of	
anticoagulation	clinic	providers	in	the	United	States.	By	combining	both	
survey	data	and	themes	from	qualitative	interviews,	we	aimed	to	better	
understand	 and	 describe	 the	 barriers	 and	 facilitators	 that	 anticoagula-
tion	clinics	experience	when	adopting	care	pathways	for	DOAC-	treated	
patients.
2  | METHODS
2.1 | Study design and subject recruitment
Our	mixed-	methods	study	involved	two	methods	of	data	collection.	
The	 quantitative	 data	 was	 collected	 via	 an	 online	 survey	 of	 anti-
coagulation	 clinic	 providers	 (Online	 Appendix).	 Details	 have	 been	
published	previously.4	Briefly,	we	invited	all	active	members	of	the	
Anticoagulation	 Forum	 (a	 large	 peer	 organization	 of	 anticoagula-
tion	service	providers	in	North	America)	to	participate	in	an	online	
survey.	We	excluded	responses	from	anticoagulation	clinics	located	
outside	 the	United	States,	 clinics	who	serviced	only	 inpatients,	or	
duplicate	responses.
The	 qualitative	 data	 was	 collected	 through	 semi-	structured	
interviews	 with	 anticoagulation	 clinic	 leaders	 (Online	 Appendix).	
During	the	survey,	 if	participants	responded	affirmatively	to	a	sur-
vey	 question	 that	 they	 possessed	 detailed	 knowledge	 about	 their	
clinic’s	staff	model,	structure,	and	policies,	they	were	subsequently	
invited	to	participate	in	a	semi-	structured	interview.	Most	of	the	in-
terviews	occurred	during	the	Anticoagulation	Forum	meeting	held	in	
Los	Angeles	in	April	2017.	Four	of	the	interviews	occurred	by	phone	
in	the	4	weeks	following	the	Anticoagulation	Forum	meeting.	All	in-
terviews	were	conducted	in	April	or	May	of	2017.
2.2 | Qualitative interview setting
A	total	of	20	qualitative	interviews	were	conducted	by	two	research	
assistants,	 one	 nurse	 practitioner,	 and	 one	 physician	 from	 the	 re-
search	team.	Interviews	were	conducted	in	person	with	anticoagula-
tion	clinic	leaders	at	the	Anticoagulation	Forum	Meeting.	Interviews	
lasted	 an	 average	 of	 35	minutes.	We	 developed	 a	 semi-	structured	
interview	 guide	 created	 to	 assess	 the	 structure,	 function,	 staffing,	
and	payment	models	in	contemporary	anticoagulation	clinics	(Online	
Appendix).	The	semi-	structured	interview	guide	attempted	to	under-
stand	the	details	of	clinic	staffing	models	and	patient	management	at	
each clinic. Interviews were audio recorded and transcribed verbatim.
2.3 | Qualitative analytic approach
Our	research	team	employed	a	three-	step	group	coding	process	when	
analyzing	the	transcripts	from	the	Anticoagulation	Forum	Conference.	
The	investigators	and	research	assistants	first	read	several	transcripts	
together	 and	 came	 to	 a	 consensus	 on	 coding	 as	well	 as	what	major	
themes	could	be	pulled	from	the	transcripts.	The	research	assistants	
and	 a	 research	 coordinator	 came	 together	 to	 develop	 a	 codebook	
using	 open	 coding	 with	 code	 names,	 meanings,	 and	 examples	 from	
the	transcripts.	The	coding	team	coded	two	interviews	separately,	and	
then	reviewed	and	discussed	edits	that	needed	to	be	made	to	the	final	
codebook	as	a	group.	This	codebook	and	the	initial	two	interviews	were	
reviewed	and	modified	in	conjunction	with	the	lead	investigator.	With	
the	final	codebook	in	place,	the	two	research	assistants	completed	cod-
ing	the	remainder	of	the	transcripts.	All	transcripts	were	coded	using	
MAXQDA	12	software	(VERBI	Software	GmbH,	Berlin,	Germany).
Once	all	the	transcripts	were	coded,	the	analytic	team	came	back	
together	 to	 identify	 relationships	 between	 codes	 and	 additional	
common	themes	throughout	the	transcripts.	Relationships	between	
different	themes	and	categories	were	analyzed	using	original	quotes	
and	by	retrieving	thematic	segments	from	the	transcripts.	Once	the	
common	 codes	 and	 themes	 were	 identified	 throughout	 the	 tran-
scripts,	the	team	developed	a	conceptual	model	displaying	the	clinic	
variation	represented,	the	clinic	challenges	discussed,	and	what	out-
comes	came	as	a	result	of	the	clinic	variation	and	challenges.
Essentials
•	 Outpatient	anticoagulation	clinics	routinely	manage	warfarin	patients.	Barriers	to	incorporating	direct	oral	anticoagulant	(DOAC)	pa-
tients	into	clinic	management	have	not	previously	been	addressed.
•	 Survey	results	from	159	anticoagulation	clinics	and	interviews	with	20	anticoagulation	clinic	providers	were	analyzed	to	identify	how	
DOAC	care	can	be	integrated	into	anticoagulation	clinics.
•	 Key	barriers	to	DOAC	care	in	the	anticoagulation	clinic	include	a	lack	of	referring	provider	awareness,	financial	challenges,	and	varia-
tions	in	clinical	knowledge	vs.	scope	of	practice	for	anticoagulation	clinic	providers.
•	 Variation	in	anticoagulation	clinic	size,	structure,	and	staffing	was	associated	with	different	barriers	to	caring	for	DOAC	patients.
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2.4 | Quantitative analytic approach
Survey	respondents	were	limited	to	those	residing	and	working	within	
the	 United	 States.	 Duplicate	 responses	 were	 eliminated	 to	 ensure	
only	 a	 single	 response	 (first	 submitted)	 from	 each	 anticoagulation	
clinic	 that	provided	outpatient	anticoagulation	care.	The	survey	de-
sign	employed	a	logic	mechanism	intended	to	minimize	the	number	of	
questions	any	single	respondent	had	to	complete.	Therefore,	results	
are	reported	only	for	the	survey	respondents	who	were	shown	each	
individual	question.	Missing	values	were	excluded	from	the	denomi-
nator	when	calculating	percentages.
Statistical	 analysis	 was	 performed	 using	 Stata	 version	 14.2	
(StataCorp,	College	Station,	 TX).	 Summary	 statistics	 (mean	±	stan-
dard	deviation	[SD]	or	median	and	interquartile	range	[IQR])	are	pre-
sented	for	all	analyses.
2.5 | Regulatory oversight and project sponsorship
This	project	was	reviewed	and	deemed	exempt	from	regulation	by	the	
University	 of	 Michigan	 institutional	 review	 board	 (HUM00126169).	
Funding	 for	 this	 survey	 and	 analysis	 was	 provided	 by	 Pfizer.	 Pfizer	
Medical	Affairs	authors	provided	input	to	study	question	development	
and	design,	but	University	of	Michigan	investigators	made	all	final	deci-
sions	regarding	survey	design,	data	analysis,	and	results	reporting.
3  | RESULTS
Three	primary	 themes	emerged	 from	 the	qualitative	 interviews	as	
key	 barriers	 to	 incorporating	 DOAC	 patients	 into	 anticoagulation	
clinic	 care	 (Figure	1).	These	were:	 (a)	 a	 lack	of	provider	awareness	
about	the	need	for	ongoing	monitoring	and	the	services	provided	by	
the	anticoagulation	clinic	for	DOAC	patients;	(b)	financial	challenges	
to	providing	care	to	DOAC-	patients	and	maintaining	the	anticoagu-
lation	clinic	budget;	and	(c)	clinical	knowledge	versus	scope	of	care	
by	the	anticoagulation	clinic	staff.	In	addition	to	these	themes,	three	
important	characteristics	of	anticoagulation	clinics	highlight	the	var-
iability	of	clinic	structures	and	function	that	impact	those	barriers.	
These	areas	of	variation	were:	(a)	the	size	and	health	system	affilia-
tion	of	the	anticoagulation	clinic;	(b)	the	use	of	face-	to-	face	versus	
telephone-	based	patient	interactions;	and	(c)	the	use	of	nurses	ver-
sus	pharmacists	to	provide	the	majority	of	anticoagulation	care.
3.1 | Clinic variation
The	159	surveyed	anticoagulation	clinics	represent	a	wide	variety	of	
models	for	care.	The	median	number	of	patients	managed	was	925,	
ranging	from	35	to	9000.	These	clinics	were	staffed	with	a	median	of	
six	full-	time-	equivalent	(FTE)	staff,	ranging	from	less	than	one	FTE	to	
30	FTE	staff	members.	Academic	affiliation	was	reported	by	31	of	159	
(19.5%)	of	 the	survey	 respondents.	Among	 the	20	 interviewees,	 six	
(30%)	self-	described	as	large	clinics	while	three	(15%)	self-	reported	as	
medium	size,	and	11	(55%)	self-	reported	as	small	sized	clinics.
Of	the	surveyed	anticoagulation	clinics,	54	of	158	(34.2%)	use	only	
a	face-	to-	face	model,	29	of	158	(18.4%)	exclusively	use	a	telephone-	
based	model,	 and	75	of	158	 (47.5%)	use	a	 combination	of	 these	ap-
proaches.	 One	 respondent	 did	 not	 indicate	 their	 model	 of	 patient	
interaction.	Among	the	20	interviewees,	four	(20%)	use	a	face-	to-	face	
model	exclusively,	eight	(40%)	primarily	use	a	telephone-	based	model,	
and	eight	(40%)	use	both	face-	to-	face	and	telephone-	based	care.	From	
the	 semi-	structured	 interviews,	 clinic	 leaders	 acknowledged	 that	 the	
size	of	their	patient	population	often	dictated	how	their	anticoagulation	
F IGURE  1 Variation	in	anticoagulation	clinic	structure	and	associated	barriers	to	integrating	direct	oral	anticoagulant	care.	DOAC,	direct	
oral	anticoagulant;	RN,	registered	nurse
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clinic	was	structured.	Smaller	clinics	serving	fewer	patients	often	de-
veloped	as	an	extension	of	a	smaller	physician	practice	and,	therefore,	
used	a	face-	to-	face	model	with	point-	of-	care	INR	testing.	Larger	clin-
ics	serving	more	outpatients	frequently	had	to	employ	a	phone-	based	
model	without	point-	of-	care	 INR	 testing	 to	accommodate	 their	 large	
patient	population.
Pharmacists	staffed	109	of	159	 (68.6%)	of	surveyed	anticoagula-
tion	clinics	and	registered	nurses	staffed	88	of	159	(55.4%)	of	clinics.	
A	minority	 of	 clinics	 (41	 of	 159,	 25.8%)	 used	 both	 pharmacists	 and	
registered	nurses	concurrently.	Among	the	20	interviewees,	11	(55%)	
used	pharmacists	and	16	(80%)	used	registered	nurses.	Similar	to	the	
survey	results,	seven	(35%)	interviewees	reported	that	their	anticoag-
ulation	clinic	used	both	pharmacists	and	registered	nurses.	From	the	
semi-	structured	interviews,	variation	in	the	scope	of	practice	by	type	
of	provider	was	confirmed.	Pharmacists	frequently	acknowledged	their	
role	(or	potential	role)	in	assisting	with	initial	decision	making	of	specific	
anticoagulants	while	nurses	expressed	that	this	was	out	of	scope	for	
their	practice.
3.2 | Barriers to DOAC care
The	first	theme	to	emerge	from	the	interviews	was	that	most	providers	
were	unaware	of	the	services	provided	by	the	anticoagulation	clinic	for	
DOAC	patients	or	the	benefits	of	referral	to	the	anticoagulation	clinic	
(Table	1).	From	the	survey	data,	83	of	159	(52.2%)	of	respondents	indi-
cated	that	their	anticoagulation	clinic	provides	care	for	DOAC	patients,	
but	the	median	estimated	percent	of	their	clinic	made	up	of	DOAC	pa-
tients	was	10%	(IQR	5%-	30%).4 There was no association between a 
clinic	offering	DOAC	care	and	the	clinic	size	(OR	1.013,	95%	CI	0.993-	
1.034,	P = 0.191	for	every	100	patients	managed	in	the	clinic).	Similarly,	
TABLE  1 Quotes	about	barriers	to	direct	oral	anticoagulant	care	in	the	anticoagulation	clinic
Code Theme Exemplar quote
Provider	unaware	system	
exists
Referring	provider	awareness “A	lot	of	patients…	they	were	a	warfarin	patient,	they	were	switched	to	
DOAC	and	cardiology	never	let	us	know,	and	at	that	point	we	were	
reaching	them	and	saying,	‘Can	you	please	place	a	referral	so	we	can	
follow	them.’	We	were	getting	a	lot	of	responses,	‘Oh,	you	follow	
them?’” 
Provider	aware	system	exists Referring	provider	awareness “I	think	that	they	all	are	aware	that	we	will	manage	and	dose	warfarin…	
Some	providers	are	aware	that	we	also	follow	DOAC	patients.	
Although	I	think	it’s	fair	to	say	that	the	majority	of	them	don’t	consider	
that	as	a	reason	to	refer.”
Financial	structure	(institu-
tional	funding)
Financial	challenges “There	have	been	discussions.	We’ve	been	down,	I’ve	been	down	
different	avenues	and	come	to	dead	ends	quite	a	few	times,	so,	we’re	
always	looking	for	ways	to	potentially	support	our	revenue.	It’s	just	it’s	
difficult	because	of	the	way	we	operate,	we	don’t	see	patients	
face-	to-	face.	We	used	to	do	the	point	of	care	but	then	that	became	a	
kind	of	a	negative	in	regards	of	revenue.”	
Concerns	about	
understaffing
Financial	challenges	 “We	need	the	admin	pharmacists	plus	we’re	also	using	a	little	bit	more	
of	sort	of	our	other	pharmacists	taking	them	away	from	face-	to-	face	
time	to	really	manage	those	phone	lists.	That’s	a	challenge	and	that,	
none	of	that	work,	you	know,	can	be	billed.”	
Financial	structure	(bill	
patients)
Financial	challenges	 “Obviously	there	is	always	going	to	be	difficulty	when	it	comes	in	terms	
of	reimbursement	purposes…because	as	pharmacists	in	our	state	we	
are	not	considered	to	be	providers	yet	so	we	can’t	bill	at	the	level	that	
we	provide	services	for…	and	so	that	has	been	a	challenge.”	
Staff	structure Clinical	knowledge	versus	scope	of	
care
“Duration	of	therapy—we	push	back	to	the	PCM	all	the	time	or	to	
hematology	or	something	like	that.	However,	I	will	say	that	I	do	a	lot	of	
counseling	of	PCMs	of	what	that	duration	of	therapy	should	be.	So,	I	
don’t	make	the	determination	myself	because	I’m	just	trying	to	cover	
myself	and	make	the	physician	be	involved.”	(interviewee	is	an	RN)	
Staff	structure Clinical	knowledge	versus	scope	of	
care
“Our	patient	list	on	the	DOACs	is	over	100	at	this	point.	Mainly	right	
now	managed	by	the	[pharmacists];	although,	RNs	like	myself	and	the	
other	RNs	that	we	have	they	do	DOAC	education,	but	they	don’t	do	
any	recommendations	for	DOAC	changes,	conversions	from	warfarin	
to	DOAC	or	vice	versa	the	case	that	is	necessary.	That	is	left	up	to	the	
pharmacist	for	their	expertise.”	
Challenges Clinical	knowledge	versus	scope	of	
care
“We	have	some	providers	that	want	to	hold	DOACs	for	five	or	seven	
days,	and	they	refuse	to	let	us	do	what	is	medically	necessary	and	safe	
for	that	patient	and	so	we	always	document	the	reason	why	and	that	
that	is	their	responsibility	not	ours.”	
DOAC,	direct	oral	anticoagulant;	PCM,	primary	care	manager;	RN,	registered	nurse.
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the	clinic	size	is	not	associated	with	the	percent	of	patients	within	the	
clinic	treated	with	DOACs	(Spearman’s	rho	−0.113,	P = 0.445).
The	second	theme	centered	around	the	many	financial	challenges	
that	anticoagulation	clinics	face	(Table	1).	The	financial	challenges	in-
cluded	financial	barriers	for	clinic	patients	(cost	of	medication)	and	fi-
nancial	difficulties	experienced	by	clinics	in	regard	to	reimbursements.	
Depending	on	how	the	clinic	is	financed,	providing	management	to	pa-
tients	who	do	not	require	point-	of-	care	testing	or	billable	face-	to-	face	
visits	is	a	significant	barrier	to	providing	care	for	DOAC	patients.	From	
the	survey,	88	of	128	(68.8%)	of	responding	clinics	report	billing	for	
clinic	services.	Details	of	specific	services	or	populations	(eg,	lab	test-
ing,	DOAC	vs	warfarin	patients)	billed	were	not	collected.	Of	these,	68	
of	88	(77.3%)	bill	both	patients	and	insurance	companies	while	18	of	
88	(20.5%)	only	bill	insurance	companies	and	2	of	88	(2.3%)	only	bill	
patients.	Billing	patients	or	insurance	companies	was	more	common	
among	clinics	that	predominantly	use	point-	of-	care	INR	testing	(80	of	
103,	93.0%)	as	compared	to	clinics	that	rely	on	standard	venipuncture	
lab	INR	results	(6	of	23,	7.0%,	P < 0.001).
The	 third	 theme	 involved	 the	 challenges	with	 clinical	 knowledge	
versus	scope	of	care	by	anticoagulation	staff	(Table	1).	While	titrating	
warfarin	dosing	and	scheduling	INR	lab	draws	is	usually	accomplished	
through	provider-	approved	protocols,	making	recommendations	around	
peri-	procedural	management	of	DOACs	or	assisting	with	drug	selection	
is	not	as	routinely	covered	by	these	same	physician-	approved	protocols.	
Additionally,	while	many	interviewees	expressed	that	their	nursing	and	
pharmacist	staff	had	clinical	knowledge	about	how	to	manage	DOACs	
(eg,	appropriate	drug	selection,	peri-	procedural	management,	dose	ad-
justment	 for	 renal	 function),	 they	frequently	saw	that	physicians	and	
other	 clinical	 providers	were	 not	 always	 following	 the	 best	 available	
evidence.	Some	interviewees	noted	a	difference	between	nursing	and	
pharmacist	staff	in	their	roles	for	DOAC	care.	From	the	survey,	assisting	
with	anticoagulant	drug	selection	was	more	common	in	clinics	that	used	
both	nurses	and	pharmacists	 (27	of	41,	65.9%)	and	pharmacists	only	
(37	of	68,	54.4%)	than	clinics	that	used	nurses	only	(17	of	47,	36.2%;	
P = 0.018).	 Similarly,	 assisting	 with	 perioperative	 management	 was	
more	common	in	clinics	that	used	both	nurses	and	pharmacists	(40	of	
41,	97.6%)	and	pharmacist-	only	clinics	(62	of	68,	91.2%)	than	nurse-	only	
clinics	(37	of	47,	78.7%;	P = 0.014).
3.3 | Overcoming barriers
The	interviewees	identified	a	number	of	potential	strategies	for	over-
coming	barriers	to	providing	DOAC	care.	The	strategies	focused	on	
the	lack	of	provider	awareness	about	the	need	for	ongoing	DOAC	care	
by	the	anticoagulation	clinic.	Interviewees	highlighted	both	local	and	
national	efforts	 to	 increase	awareness	among	 the	broader	provider	
population.	These	efforts	include	informational	meetings	led	by	medi-
cal	directors	and	anticoagulation	clinic	staff,	as	well	as	integrating	anti-
coagulation	clinic	awareness	to	physician	and	staff	orientation.
“We’ve	presented	at	some	meetings	and,	you	know,	
grand	rounds	and	so	forth	to	kind	of	 let	them	know	
we	can	offer	that	service.”
“Each	 new	 provider	 that	 comes	 into	 the	 facility	 is	
trained	 on	 how	 to	 refer	 and	 they	 are	 required	 in	
their	 training	 process	 to	 do	 a	 training	 session	 on	
anticoagulation.”
Interviewees	 also	 discussed	 innovative	 uses	 of	 automatic	 elec-
tronic	medical	record	search	functions	to	identify	patients	in	need	of	
anticoagulation	clinic	services.
“We	also,	through	Epic,	through	Healthy	Planet,	have	
reports	 that	 will	 let	 us	 know	 the	 patients	 that	 are	
scheduled	 for	 procedures,	 uh,	 as	 well	 as	 the	 major	
drug-	drug	 interactions	 as	 long	 as	 it’s	 prescribed	
within our system.”
Finally,	they	identified	the	potential	role	that	published	literature	
and	national	organizations	(such	as	the	Anticoagulation	Forum)	can	
have	on	raising	awareness	for	DOAC	care	within	an	anticoagulation	
clinic	setting.
“I	guess	the	biggest	ways	these	forums	can	help	is	any	
kind	of	 literature	that	can	show	that	they	should	be	
tracked	on	a	regular	basis.”
“But	 I	 do	 see	 where	 [Anticoagulation]	 Forum	 could	
play	a	role	in	that	if	they	can	provide	national	experts	
who	are	saying,	‘Yes	there	is	value	to	DOAC	manage-
ment,’	we	have	something	 to	go	back	on,	 instead	of	
it’s	just	us.	We’re	not	just	trying	to	keep	our	job,	we	
see	this	as	a	value	to	patients.”
4  | DISCUSSION
In	this	mixed-	methods	study	of	anticoagulation	clinic	providers,	key	
barriers	to	integrating	care	of	DOAC	patients	included	lack	of	refer-
ring	provider	awareness,	fiscal	challenges,	and	clinic	staff	knowledge	
versus	 their	 scope	of	 care.	 These	barriers	were	 largely	 influenced	
by	the	size	and	type	of	anticoagulation	clinic,	the	method	by	which	
patients	 interacted	with	the	clinic	and	had	 INR	 labs	collected,	and	
the	 staff	who	comprised	 the	anticoagulation	clinic	 (nursing	versus	
pharmacist).	These	findings	were	reflected	in	both	the	broad	survey	
responses	as	well	as	the	semi-	structured	interviews	conducted	with	
anticoagulation	clinic	leaders.
Although	many	clinicians	focused	on	the	lack	of	routine	labo-
ratory	monitoring	 for	DOAC	patients,	 there	has	not	been	as	 ro-
bust	a	consideration	for	the	other	services	anticoagulation	clinics	
provide	patients	and	how	DOAC-	treated	patients	might	benefit.	
Our	 study	 highlights	 that	 most	 anticoagulation	 clinic	 providers	
and	 leaders	 recognize	 an	 important	 role	 in	 helping	 to	 care	 for	
these	 patients;	 however,	 they	 experience	 important	 barriers	 to	
implementing	protocols	and	clinical	pathways	for	DOAC	care.	We	
have	 previously	 highlighted	 the	 role	 that	 anticoagulation	 clinics	
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should	have	in	assisting	with	DOAC	management.	These	include	
providing	assistance	with	drug	and	dose	 selection,	ongoing	 lab-
oratory	monitoring	 (especially	of	 renal	 function),	 and	assistance	
with	peri-	procedural	management.	Each	of	these	is	a	key	patient	
safety	 support	 process	 that	 may	 help	 to	 reduce	 the	 frequent	
emergency	department	visits	for	adverse	drug	events	and	other	
medication-	related	complications.
Understanding	the	barriers	is	an	important	step	to	implementing	
new	protocols	or	clinical	pathways	to	care	for	DOAC	patients.	Many	
other	 determinants	 of	 successful	 program	 implementation	 are	 also	
important	 to	 consider.	 For	 example,	 it	 is	 crucial	 to	 justify	 the	 rea-
son	for	DOAC	management	pathways	within	anticoagulation	clinics.	
Therefore,	more	robust	evidence	to	define	the	frequency	and	conse-
quence	of	inappropriate	prescribing	would	better	solidify	the	“problem	
gap	to	be	closed.”	Next,	evidence	showing	that	referral	to	an	antico-
agulation	clinic	can	reduce	this	gap	in	care	would	help	anticoagulation	
clinic	managers	justify	their	care	delivery	program.	Similarly,	outlining	
the	frequency	with	which	DOAC	medications	are	mismanaged	before	
a	 surgical	 procedure,	 leading	 to	 cancelations,	 poor	 patient	 satisfac-
tion,	or	adverse	clinical	events	must	be	measured	and	reported.	Then,	
evidence	supporting	improved	care	through	an	anticoagulation	clinic	
model	would	improve	the	likelihood	of	broad	practice	adoption.
Our	study	has	a	number	of	important	strengths.	The	use	of	mixed-	
methods	allows	for	us	to	combine	the	richness	of	a	qualitative	analysis	
with	the	generalizability	of	a	quantitative	study.	In	this	way,	we	have	
been	 able	 to	 identify	 key	 themes	 that	 emerged	 from	 the	20	 inter-
viewees	and	explore	their	generalizability	across	the	broader	survey	
respondents.	Second,	we	believe	that	this	is	the	first	in	depth	report	
on	barriers	and	facilitators	to	DOAC	care	within	the	anticoagulation	
clinic.	A	few	limitations	are	important	to	mention	as	well.	First,	as	with	
all	survey	and	qualitative	work,	we	are	only	able	to	comment	on	data	
from	willing	survey	respondents	and	interviewees.	Additionally,	while	
the	AC	Forum	is	the	largest	organization	of	anticoagulation	providers	
in	North	America,	its	membership	is	not	compulsory	or	inclusive	of	all	
anticoagulation	clinics.	These	features	may	limit	the	generalizability	
of	our	findings.	Second,	due	to	the	heterogeneity	of	anticoagulation	
clinic	structures,	each	and	every	finding	from	this	analysis	may	not	be	
applicable	to	all	anticoagulation	clinics.	While	clinical	knowledge	ver-
sus	scope	of	care	was	a	significant	barrier	identified	in	the	interviews,	
we	do	not	have	data	on	the	frequency	of	physician-	level	support	for	
the	anticoagulation	clinics	from	the	survey	data.	Additionally,	we	did	
not	 interview	 anticoagulation	 clinic	managers	 from	 clinics	 that	 did	
not	manage	DOAC-	treated	patients.	Finally,	as	with	all	observational	
research,	we	are	only	able	to	comment	on	association	and	not	causal-
ity.	By	pairing	quantitative	findings	with	qualitative	findings,	we	are	
about	to	strengthen	the	likely	association	between	our	key	findings.
In	summary,	anticoagulation	clinics	in	the	United	States	identify	three	
key	barriers	to	integrating	care	for	DOAC	patients	into	their	work	flow.	
These	barriers	are	likely	related	to	the	diversity	in	anticoagulation	clinic	
structure	and	 function.	While	 some	clinics	have	developed	 innovative	
strategies	 to	 overcome	 some	 barriers,	 more	work	 is	 needed	 to	more	
broadly	implement	anticoagulation	clinic	care	for	DOAC-	treated	patients.
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